Product category:
Laboratory and scientific books and publishing
News Release from: Frost and Sullivan | Subject: World Gene Therapy Markets
Edited by the Laboratorytalk Editorial
Team on 01 August 2005
Gene therapy market set to grow
Participants in the gene therapy market discover new ways to improve clinical efficiency and generate revenue, according to this market analysis
The gene therapy market has had limited success with products during the clinical development process Due to toxicological complications and poor therapy efficacy, healthcare authorities have suspended several gene therapy trials worldwide
This article was originally published on Laboratorytalk on 2 Aug 2002 at 8.00am (UK)
Related stories
Smart materials: the new frontier of technology
Analysis reveals the advances made in the development of industrial applications for smart, active, or engineered materials, including their use in smart structures
Ready for convergence?
The convergence of nanotechnology, biotechnology, information technology, and cognitive science will have a substantial impact on companies and markets in the future
However, research involving novel designs for vectors, methods of introducing 'naked' deoxyribonucleic acid (DNA), and the use of electroporation to improve DNA uptake into cells have been successful in pre-clinical studies.
These new-age technologies are now entering the clinical development stage and approaching the market.
New analysis from Frost and Sullivan, World Gene Therapy Markets, reveals that revenue in this industry is expected to total US$150 million in 2005 and could reach $5,750 million in 2011.
Further reading
European cardiac risk assessment markers
Elevated European CHF mortality rates and introduction of premium-priced assays stimulate uptake of cardiac risk assessment markers, according to new research
Bubble bursts in defoamer market
Negative growth will force European pulp and paper defoamer suppliers to recognise commodity market, says new report
Banking on blood
The blood banking devices market will continue to post steady figures, aided by the industry's flexibility and adaptability to changing market needs and technological advancements
An increasingly popular method of improving clinical efficiency is to combine gene therapy trials with conventional therapeutics.
These combination trials sometimes involve collaborations outside the gene therapy market with companies having established products or expertise in healthcare.
"A second strategy - particularly for companies with fewer products in development - is to work out a suitable exit strategy, should a gene therapy product fail during clinical development," explains Frost and Sullivan industry analyst Phil Webster.
"This involves the objective assessment of a project, which can either be terminated or have its components recycled into a new project".
The gene therapy market has been on a rollercoaster ride with devastating clinical failures balanced by incredible breakthroughs for the treatment of severe diseases.
The launch of Gendicine in China, the only gene therapy product available in the market, signifies a huge boost for gene therapy.
Due to safety concerns, poorly regulated trials, and high levels of clinical attrition, regulatory agencies have stringent authorisation laws about gene therapy.
Specific ethics commissions, regulatory divisions, and governmental panels all over the world inspect and monitor trials by gene therapy companies.
Lack of cellular target specificity is largely responsible for the toxicity issues in gene therapy, as viral vectors, the most commonly used gene delivery system, may infect even healthy cells while transporting genes to the body.
There is the danger of the new gene being inserted in the wrong location in the DNA that can possibly cause cancer or other mutations.
Even over-expression of the introduced gene sequences can cause an unfavourable immune reaction.
"Trends in clinical development have shown that there is significant focus on terminal diseases such as monogenic and oncology disorders," notes Webster.
"There is also an increasing trend in non-terminal cardiovascular disorders, wherein existing products are available to significantly prolong the life of a patient but do not necessarily offer a cure".
The historically associated risks of gene therapy are now lessening, predominantly through scientific advances in gene delivery by industry participants.
Regulatory restrictions will diminish if the clinical success rate improves and more products are submitted for approval.
World Gene Therapy Markets is part of Frost and Sullivan's Pharmaceuticals subscription.
It examines the status of the worldwide gene therapy market with a focus on its benefits, drawbacks, and upcoming trends.
This research service identifies key trends in gene therapy for oncology, cardiovascular and monogenic indications.
It also investigates short- to medium-term product launches through an analysis of clinical pipelines for gene therapy products.
• Frost and Sullivan: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
